AI assistant
Kymera Therapeutics, Inc. — Director's Dealing 2025
Apr 9, 2025
31145_dirs_2025-04-09_0b143b3a-6f10-47af-a97d-80407ceebe52.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kymera Therapeutics, Inc. (KYMR)
CIK: 0001815442
Period of Report: 2025-04-08
Reporting Person: Goodman Noah (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-04-08 | Common Stock | A | 50000 | — | Acquired | 50081.438 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-04-08 | Stock Option (Right to Buy) | $21.05 | A | 100000 | Acquired | 2035-04-07 | Common Stock (100000) | Direct |
Footnotes
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following April 8, 2025, subject to the reporting person's continued employment through each vesting date.
F2: Twenty-five percent (25%) of the shares underlying this stock option shall vest on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.